ArticleIranian journal of basic medical sciences2017
Berberine protects against glutamate-induced oxidative stress and apoptosis in PC12 and N2a cells.
Article in Iranian journal of basic medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Anti-seizure Effects and Mechanisms of Berberine: A Systematic Review.Current pharmaceutical biotechnology · 2024Pooled it
- Apigenin Mitigates PFOA-Induced Activation of the NLRP3-Pyroptosis Axis and Associated Neurological Damage.Environment & health (Washington, D.C.) · 2026Article
- Protective effects of berberine against diabetes-associated cognitive decline in mice.Acta diabetologica · 2025Article
- Allocryptopine, tetrahydropalmatine, and tetrahydroberberine N-oxide alkaloids alleviate cellular stress by modulating calcium homeostasis and the MAPK and akt/GSK-3β/tau signaling pathways.Frontiers in pharmacology · 2025Article
- Oligoprotective Activity of Levetiracetam against Glutamate Toxicity: AnCurrent pharmaceutical design · 2025Article
- Neuroprotective Effect ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Neuroprotective effect and preparation methods of berberine.Frontiers in pharmacology · 2024Review
- 3'-Daidzein Sulfonate Sodium Protects against Glutamate-induced Neuronal Injuries by Regulating NMDA Receptors.Current pharmaceutical design · 2024Article
- Neuroprotective Properties of Berberine: Molecular Mechanisms and Clinical Implications.Antioxidants (Basel, Switzerland) · 2023Review
- Neuronal nitric oxide synthase/reactive oxygen species pathway is involved in apoptosis and pyroptosis in epilepsy.Neural regeneration research · 2023Article
- The neuroprotective potential of phytochemicals in traumatic brain injury: mechanistic insights and pharmacological implications.Frontiers in pharmacology · 2023Review
- The Regulatory Effects of Taurine on Neurogenesis and Apoptosis of Neural Stem Cells in the Hippocampus of Rats.Advances in experimental medicine and biology · 2022Article
- Berberine: A Promising Treatment for Neurodegenerative Diseases.Frontiers in pharmacology · 2022Review
- Network Pharmacology-Based Strategy to Investigate the Pharmacologic Mechanisms of Coptidis Rhizoma for the Treatment of Alzheimer's Disease.Frontiers in aging neuroscience · 2022Article
- Neuroprotective Potential of Berberine Against Doxorubicin-Induced Toxicity in Rat's Brain.Neurochemical research · 2021Article
- Optimization of nutritional and environmental conditions for pyocyanin production by urine isolates ofSaudi journal of biological sciences · 2021Article
- Antioxidant, antimicrobial and neuroprotective effects of Octaviania asterosperma in vitro.Mycology · 2020Article
- Berberine protects against diabetic retinopathy by inhibiting cell apoptosis via deactivation of the NF‑κB signaling pathway.Molecular medicine reports · 2020Article
- Attenuation of Nrf2/Keap1/ARE in Alzheimer's Disease by Plant Secondary Metabolites: A Mechanistic Review.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesNeurodegenerative diseases have been associated with glutamatergic dysfunction. Berberine, an isoquinoline alkaloid broadly present in different medicinal herbs, has been reported to have neuroprotective effect. In the present study, the effects of berberine against glutamate-induced oxidative damage and apoptosis were investigated. MATERIALS AND
methodsThe cultured PC12 and N2a cells were pretreated (2 hr) with varying concentrations of berberine (50-1000 µM), followed by exposure to glutamate (10 mM) for 24 hr. The cells viability, intracellular reactive oxygen species (ROS), lipid peroxidation, glutathione (GSH) content, superoxide dismutase (SOD) activity, DNA fragmentation and the expressions of pro-apoptotic (cleaved caspase-3 and bax) and anti-apoptotic (bcl-2) proteins were then measured.
resultsIn both cell lines, pretreatment with berberine (especially at low concentrations) significantly decreased ROS generation, lipid peroxidation, and DNA fragmentation, while improving glutathione content and SOD activity in glutamate-injured cells. Moreover, berberine showed anti-apoptotic effects by reducing the glutamate-evoked caspase-3 and bax/bcl-2 overexpression.
conclusionThe results of present study suggest that berberine protects against glutamate-induced PC12 and N2a cells injury by decreasing oxidative stress and subsequently inhibiting apoptosis. This is relevant to berberine treatment in neurodegenerative disorders, such as dementia (Alzheimer's disease), seizures, and stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.